NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2016-01-31

Study Completion Date

2017-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This phase II trial studies the safety of NovoTTF-100A in combination with bevacizumab and carmustine and to see how well they work in treating patients with glioblastoma multiforme that has returned for the first time. NovoTTF-100A, a type of electric field therapy, delivers low intensity, alternating "wave-like" electric fields that may interfere with multiplication of the glioblastoma multiforme cells. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as carmustine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving NovoTTF-100A together with bevacizumab and carmustine may be an effective treatment for glioblastoma multiforme.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM)

NCT00379470

Recurrent Glioblastoma Multiforme

COMPLETED PHASE3

NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme

NCT01954576

Glioblastoma Brain Neoplasms

TERMINATED NA

Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme

NCT00068952

Glioblastoma

COMPLETED PHASE3

Optune(NOVOTTF-100A)+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344)

NCT01925573

RECURRENT GLIOBLASTOMA Brain Tumor

TERMINATED NA

Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

NCT06344130

Astrocytoma Glioma Recurrent Glioblastoma

RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. Establish the safety of NovoTTF-100A in combination with bevacizumab and BCNU (carmustine) in glioblastoma multiforme (GBM) patients who have relapsed after chemoradiation therapy (first relapse).

II. Determine the 6 month overall survival (OS). III. Determine the 6 month progression free survival (PFS). IV. Evaluate the effect of this therapy regimen on quality-of-life.

OUTLINE:

Patients receive bevacizumab intravenously (IV) over 30-90 minutes every 2 weeks beginning on day -7 for up to 13 doses and carmustine IV over 4 hours every 8 weeks beginning on day 1 for up to 3 doses. Patients also undergo NovoTTF-100A according to standard procedures starting one week before the first dose of carmustine.

After completion of study treatment, patients are followed up for 12 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Adult Brain Glioblastoma Recurrent Adult Brain Neoplasm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment (bevacizumab, carmustine, NovoTTF-100A)

Patients receive bevacizumab IV over 30-90 minutes every 2 weeks beginning on day -7 for up to 13 doses and carmustine IV over 4 hours every 8 weeks beginning on day 1 for up to 3 doses. Patients also undergo NovoTTF-100A according to standard procedures starting one week before the first dose of carmustine.

Group Type EXPERIMENTAL

Electric Field Therapy

Intervention Type PROCEDURE

Undergo NovoTTF-100A

Bevacizumab

Intervention Type BIOLOGICAL

Given IV

Carmustine

Intervention Type DRUG

Given IV

Quality-of-Life Assessment

Intervention Type OTHER

Ancillary studies

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Electric Field Therapy

Undergo NovoTTF-100A

Intervention Type PROCEDURE

Bevacizumab

Given IV

Intervention Type BIOLOGICAL

Carmustine

Given IV

Intervention Type DRUG

Quality-of-Life Assessment

Ancillary studies

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Avastin rhuMab-VEGF FDA 0345 Quality of Life Assessment

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed GBM
* Progressive disease after temozolomide and radiation therapy (in "first relapse")
* At least 28 days since chemotherapy or radiation
* Karnofsky performance score at least 70%
* Platelet count \>= 130/mm\^3
* Absolute neutrophil count \>= 1500/mm\^3
* Calculated creatinine clearance greater than 45 mg/dl using the Cockcroft-Gault formula
* Aspartate aminotransferase (AST) \< 2 times the upper limit of normal
* Bilirubin \< 1.5 times the upper limit of normal
* Subjects with child-bearing potential agree to use effective means of contraception

Exclusion Criteria

* Prior systemically administered nitrosoureas or vascular endothelial growth factor (VEGF) targeted therapy
* Chemotherapy for glioma other than temozolomide or Gliadel wafers (steroids are allowed)
* Pregnant or breast feeding
* Active inflammatory bowel disease
* Abdominal fistula, gastrointestinal (GI) perforation, or intra-abdominal abscess within 6 months
* Hypertension: systolic blood pressure (SBP) \> 150 or diastolic blood pressure (DBP) \> 100 mm mercury (Hg) despite antihypertensive medications
* New York Heart Association (NYHA) grade II or greater congestive heart failure (CHF); myocardial infarction or unstable angina within 6 months
* History of thrombosis
* Symptomatic peripheral vascular disease, stroke or transient ischemic attack within 6 months
* Bleeding risks: Required to be on therapeutic anticoagulation (aspirin is allowed), coagulopathy (e.g. hemophilia or von Willebrand's disease); any grade III or greater hemorrhage, major surgical procedure, or significant trauma within 28 days; core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days
* Activated partial thromboplastin time (APTT) must not exceed 32.5 seconds (normal range 21.8-31.5 seconds); international normalized ratio (INR) must not exceed 1.30 (normal range 0.87-1.18)
* Serious, non-healing wound, ulcer, or bone fracture
* Active implanted medical device (e.g. deep brain stimulators, spinal cord stimulators, vagus nerve stimulators, pacemakers, defibrillators, and programmable shunts), a skull defect (such as missing bone with no replacement), a shunt, or bullet fragments
* Known sensitivity to conductive hydrogels like the gel used on electrocardiogram (ECG) stickers or transcutaneous electrical nerve stimulation (TENS) electrodes
* Human immunodeficiency virus (HIV) positive
* Proteinuria at screening as demonstrated by urine dipstick \>= 2+
* Prior organ transplantation
* Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
* Aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), clopidogrel or any other drug whose goal is to inhibit platelet function
* Unable to give signed informed consent

Minimum Eligible Age

22 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No